Browsing by Author "Brown, Christopher B."
Now showing 1 - 7 of 7
Results Per Page
Sort Options
Item Open Access Characterization of novel granulocyte-macrophage colony-stimulating factor receptor variants in human hematopietic cells(2006) Pelley, Jennifer L.; Brown, Christopher B.Item Open Access Developing a transgenic mouse model expressing soluble gm-csf receptor alpha subunit to study its physiopathological functions(2007) Tillier, Bruno Jean; Brown, Christopher B.Item Open Access Item Open Access Investigating the binding interaction between granulocyte-macrophage colony-stimulating factor and the soluble alpha subunit of its receptor through hydrogen deuterium exchange mass spectrometry(2006) Vande Graaf, Jaclyn Louise; Brown, Christopher B.; Schriemer, David C.Item Open Access Production and evaluation of a recombinant murine soluble GM-CSF receptor alpha subunit as a GM-CSF antagonist(2006) Dai, Jeffrey Chih-Hsiang; Brown, Christopher B.Item Embargo The role of lipid rafts in rituximab-mediated apoptosis(2005) Unruh, Tammy L.; Deans, Julie; Brown, Christopher B.Item Open Access Zoster prophylaxis after allogeneic hematopoietic cell transplantation using acyclovir/valacyclovir followed by vaccination(American Society of Hematology, 2016) Jamani, Kareem; MacDonald, Judy; Lavoie, Martin; Williamson, Tyler S.; Brown, Christopher B.; Chaudhry, Ahsan; Jimenez-Zepeda, Victor H.; Duggan, Peter; Tay, Jason; Stewart, Douglas; Daly, Andrew; Storek, JanVaricella zoster virus (VZV) disease (usually cutaneous zoster) occurs frequently after hematopoietic cell transplantation (HCT), and postherpetic neuralgia (PHN) results in poor quality of life. The optimal prophylaxis of VZV disease/PHN has not been established. At our center, before 2008, VZV prophylaxis consisted of ∼1 year of post-HCT acyclovir/valacyclovir (“old strategy”), whereas post-2008 prophylaxis consisted of 2 years of acyclovir/valacyclovir followed by immunization using varicella vaccine (“new strategy”). We performed a retrospective study comparing the cumulative incidence of VZV disease and PHN among patients who completed the old strategy (n = 153) vs the new strategy (n = 125). Patients who completed the old strategy had a significantly higher cumulative incidence of VZV disease (33% vs 17% at 5 years, P ≤ .01) and PHN (8% vs 0% at 5 years, P = .02). In conclusion, VZV prophylaxis with 2 years of acyclovir/valacyclovir followed by vaccination appears to result in a low incidence of VZV disease and may eliminate PHN.